A randomized, placebo-controlled Phase 2 study of semaglutide + cilofexor + firsocostat in patients with compensated cirrhosis due to metabolic dysfunction–associated steatohepatitis (WAYFIND).

We assessed the efficacy and safety of semaglutide (SEMA; glucagon-like peptide-1 receptor agonist) alone and in fixed-dose combina-
tion with cilofexor (CILO; farnesoid X receptoragonist) and firsocostat (FIR; liver-targeted acetyl-CoA carboxylase inhibitor) in patients (pts) with compensated cirrhosis (F4C) due to metabolic dysfunction-associated steatohepatitis (MASH; NCT04971785).

Conference

AASLD 2025